Guidant buys into developer of stroke device:
This article was originally published in Clinica
Guidant has bought an equity stake of an undisclosed size in Neuroperfusion. The investment was part of a round of venture capital financing raised by Neuroperfusion. Based in Irvine, California, the company is developing a catheter-based approach to treating victims of acute ischaemic stroke. With its technology, oxygenated blood sourced from an artery in the leg is pumped in a reverse direction into veins in the brain. The reversal of flow is intended to support the brain tissue until either the clot resolves or another interventional device is introduced to unblock the artery.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.